Drugs / Norethindrone/ethinyl estradiol
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01209143 | Nov 2010 → Mar 2012 | — | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Norethindrone/ethinyl estradiol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01209143 ↗ |
| Known as | Ortho-Novum 1/35 | “Participants received the oral contraceptive norethindrone 1 mg/ethinyl estradiol 35 µg (Ortho-Novum 1/35®) orally on Days 1 and 8 of the study.” NCT01209143 ↗ |
| Route | Oral | “norethindrone 1 mg/ethinyl estradiol 35 µg (Ortho-Novum 1/35®) orally on Days 1 and 8 of the study” NCT01209143 ↗ |